Notch Intracellular Domain Expression in Various Skin Fibroproliferative Diseases

Jung-Eun Kim, Joo-Hyun Lee, Kwan-Ho Jeong, Gyong Moon Kim, Hoon Kang

Department of Dermatology, School of Medicine, The Catholic University of Korea, Seoul, Korea

Background: The effects of the Notch signaling pathway in fibroproliferative skin diseases have not been fully elucidated. Objective: The aim of this study was to investigate the expression of activated Notch signaling molecules in various skin fibroproliferative diseases. Methods: Immunohistochemical analysis of Notch intracellular domain (NICD) expression in keloid, hypertrophic scar, morphea, dermatofibroma, and normal control skin specimens was performed, and the clinical characteristics of patients with various skin fibroproliferative diseases were analyzed. Results: NICD was highly expressed in fibroblasts of keloids and moderately to highly expressed in hypertrophic scars and dermatofibromas, whereas low or no expression was detected in the fibroblasts of normal skin specimens and morpheas. NICD was constitutively expressed in keratinocytes, endothelial cells, and immune cells in normal skin specimens. Conclusion: NICD was significantly expressed in human fibroproliferative skin disorders, especially keloids, suggesting that an activated Notch signaling pathway is involved in the pathogenesis of skin fibrosis. (Ann Dermatol 26(3) 332 ∼ 337, 2014)

Keywords-Benign fibrous histiocytoma, Hypertrophic cicatrix, Keloid, Localized scleroderma, Notch receptors

INTRODUCTION

Notch signaling influences cell fate determination by modulating cell proliferation, differentiation, apoptosis, migration, and invasion. The Notch family is composed of 4 Notch receptors (Notch-1 − Notch-4), and 5 Notch ligands, including Jagged-1 (JAG-1), JAG-2, Delta-like-1, Delta-like-3, and Delta-like-4. Notch activation results in the following mechanisms: proteolytic cleavage of the Notch receptor by a metalloprotease ADAM17; formation of the γ-secretase complex; and the subsequent release of the Notch intracellular domain (NICD), which is then translocated to the nucleus to activate specific target genes such as hes-1. The pathologic activation of Notch signaling has been implicated in the pathogenesis of various malignancies and fibrotic diseases, such as systemic sclerosis and idiopathic pulmonary fibrosis. The inhibition of Notch signaling has been adopted in clinical trials to treat several malignant tumors such as gastrointestinal neuroendocrine tumors, metastatic thyroid cancer, and advanced breast cancer. Recent studies have demonstrated the anti-fibrotic effects of Notch signaling inhibition in vitro and genetic inhibition of Notch signaling in murine fibrosis models. A recent study showed that NICD and hes-1 levels increased in skin fibroblasts stimulated by TGF-β in patients with systemic sclerosis. Inhibiting the activation of the Notch receptor attenuates TGF-β-induced α-smooth muscle actin expression.
The role of the Notch signaling pathway in fibroproliferative skin diseases has not been fully elucidated. Therefore, the aim of this study was to investigate NICD expression in normal skin specimens and fibroproliferative skin diseases, including keloids, hypertrophic scars, morpheas, and dermatofibromas.

**MATERIALS AND METHODS**

**Patients and skin biopsy specimens**

This study was approved by the ethical committee of The Catholic University of Korea, and all patients signed an informed consent. The study was conducted according to the Declaration of Helsinki principles. The following formalin-fixed, paraffin-embedded specimens were retrieved: 5 normal human tissues, 5 morpheas, 5 hypertrophic scars, 5 dermatofibromas, and 5 keloids. The clinical information of patients is described in Table 1.

**Immunohistochemistry**

The specimens after fixation in 4% paraformaldehyde were embedded in paraffin for histological or immunohistochemical examinations. All immunohistochemical stainings were performed using a Dako Envision kit (Dako Cytomation Co., Glostrup, Denmark) according to the manufacturer’s instructions, using a commercially available prediluted monoclonal antibody against the Notch-1 (Abcam).

**Table 1. Clinical data of patients with fibroproliferative skin disorders**

| Patient No. | Sex/age (yr) | Site          | Disease duration | Clinical and histopathological diagnosis                          | Immunopositive cell count (%) of the NICD |
|-------------|--------------|---------------|------------------|-----------------------------------------------------------------|------------------------------------------|
| 1           | M/64         | Ant chest     | 6 months         | Keloid                                                          | 98                                       |
| 2           | F/17         | Rt auricle    | 1 year           | Keloid                                                          | 90                                       |
| 3           | F/26         | Lt earlobe    | 4 years          | Keloid                                                          | 98                                       |
| 4           | F/40         | Abdomen       | 5 years          | Keloid                                                          | 95                                       |
| 5           | F/32         | Lt earlobe    | 10 years         | Keloid, recurred 1 year after laser treatment                  | 95                                       |
| 6           | M/40         | Lt thigh      | 10 years         | Dermatofibroma                                                  | 60                                       |
| 7           | F/24         | Lt upper arm  | 4 years          | Dermatofibroma                                                  | 98                                       |
| 8           | F/24         | Rt thigh      | 3 years          | Dermatofibroma                                                  | 80                                       |
| 9           | M/41         | Rt ring finger| 1 year           | Dermatofibroma                                                  | 95                                       |
| 10          | F/52         | Lt forearm    | 20 years         | Dermatofibroma                                                  | 50                                       |
| 11          | F/53         | Lt thigh      | 7 years          | Hypertrophic scar                                              | 98                                       |
| 12          | F/52         | Lt 5th toe    | 2 years          | Hypertrophic scar                                              | 80                                       |
| 13          | M/25         | Ant chest     | 3 years          | Hypertrophic scar                                              | 80                                       |
| 14          | F/44         | Lt forearm    | 5 years          | Hypertrophic scar, recurred 1 year after excision              | 60                                       |
| 15          | F/33         | Ant chest     | 4 years          | Hypertrophic scar                                              | 95                                       |
| 16          | M/54         | Rt breast     | 2 years          | Morphea                                                         | 0                                        |
| 17          | M/46         | Lt upper back | 2 years          | Morphea                                                         | 15                                       |
| 18          | M/44         | Back          | 10 years         | Morphea                                                         | 0                                        |
| 19          | M/35         | Lt upper back | 6 months         | Morphea                                                         | 0                                        |
| 20          | M/35         | Rt lower back | 8 months         | Morphea                                                         | 19                                       |

M: male, F: female, Ant: anterior, Rt: right, Lt: left, NICD: Notch intracellular domain.

**Table 2. Immunohistochemistry of NICD in various fibroproliferative skin diseases and normal controls**

|                      | Intensity of immunostaining |
|----------------------|----------------------------|
|                      | 0  | (+) | (+++) | (+++)  |
| Keloids (n=5)        |    |     |       |       |
| Keratinocytes        | 5  |     |       |       |
| Endothelial cells    | 5  |     |       |       |
| Fibroblasts          | 5  |     |       |       |
| Immune cells         | 1  | 4   |       |       |
| Hypertrophic scar (n=5) |    |     |       |       |
| Keratinocytes        | 2  | 3   |       |       |
| Endothelial cells    | 1  | 4   |       |       |
| Fibroblasts          | 1  | 4   |       |       |
| Immune cells         | 2  | 3   |       |       |
| Dermatofibroma (n=5) |    |     |       |       |
| Keratinocytes        | 5  |     |       |       |
| Endothelial cells    | 5  |     |       |       |
| Fibroblasts          | 2  | 3   |       |       |
| Immune cells         | 1  | 4   |       |       |
| Morphea (n=5)        |    |     |       |       |
| Keratinocytes        | 1  | 4   |       |       |
| Endothelial cells    | 1  | 4   |       |       |
| Fibroblasts          | 3  | 2   |       |       |
| Immune cells         | 1  | 2   | 2     |       |
| Normal control (n=5) |    |     |       |       |
| Keratinocytes        | 1  | 4   |       |       |
| Endothelial cells    | 1  | 4   |       |       |
| Fibroblasts          | 4  | 1   |       |       |
| Immune cells         | 3  | 2   |       |       |

The degree of expression was categorized as follows: 0, 0% positive; +, 1%~19% positive; ++, 20%~79% positive; and ++++, 80%~100% positive. NICD: Notch intracellular domain.
antigen at a 1 : 200 dilution. Immunohistochemical analysis was performed on samples (Table 1, 2), and the degree of expression was semiquantitatively graded as follows: +, 1% to 19% positive; ++, 20% to 79% positive; ++++, 80% to 100% positive. Two independent dermatopathologists scored the samples of 3 high-powered fields per section, and the average score was calculated. All statistical analyses were performed using SPSS software ver. 15.0.1 (SPSS Inc., Chicago, IL, USA).

RESULTS

Keloids and hypertrophic scars
NICD in keloid and hypertrophic scar fibroblasts showed moderate to high immunoreactivity; similar observations were noted in keratinocytes, endothelial cells, and immune cells (Fig. 1 ∼ 3, Table 1). In contrast, the extracellular matrix did not express NICD in both tumors. The pattern of NICD expression showed diffuse immunoreactivity in almost all fibroblastic foci of keloids and hypertrophic scars (Fig. 1A, B). Two patients presented recurrent keloids and hypertrophic scars after laser treatment and excision, respectively. Specimens from both these patients exhibited moderate expression of fibroblast NICDs. NICD expression patterns did not vary according to disease duration, site of lesion, and recurrence history.

Dermatofibromas
Dermatofibromas also showed a similar degree of immunoreactivity for NICD in the tumor cells as well as in keloids and hypertrophic scars (Fig. 1C, 2D, 2E, 3, Table 1). Moderate to high immunoreactivity for NICD was detected in the overlying epidermal proliferation but was not detected in the grenz zone (Fig. 1C). The NICD expression pattern showed diffuse immunoreactivity in fibrohistiocytic proliferation arranged in a storiform pattern in dermatofibromas (Fig. 1C, 2D). The proliferation of fibroblast-like spindle cells, histiocytes, and vessels were uniformly stained for NICD (Fig. 2D, E).

Morpheas
NICD expression was generally low in morphea fibroblasts, whereas high expression was detected in keratinocytes and endothelial cells (Fig. 1D, 2F, 3, Table 1). Interestingly, inflammatory infiltrate in a specimen of early morphea lesion showed moderate immunoreactivity for NICD (Fig. 2G). The intensity of the immunopositivity of NICD varied at varied with areas in the same specimens in morphea tissue.

Normal skin specimens
NICD expression was generally low or not detected in fibroblasts of normal control cells, but high expression

Fig. 1. Immunohistochemical analysis of Notch intracellular domain expression in skin samples from fibroproliferative skin disorders and healthy controls. Keloid (A), hypertrophic scar (B), dermatofibroma (C), morphea (D), and normal control (E) (A, C, D, E: ×100; B: ×40).
Fig. 2. Immunohistochemical localization of Notch intracellular domain (NICD) in keloid (A, B), hypertrophic scar (C), dermatofibroma (D, E), morphea (F, G), and normal control (H). Keloid fibroblasts showed more intense immunoreactivity than hypertrophic scar and dermatofibroma fibroblasts. Strong to moderate NICD expression is observed in fibroblasts, endothelial cells and infiltrating immune cells in all specimens. Asterisks indicate vessels; arrowheads indicate fibroblasts; arrows indicate infiltrating immune cells (A, C, D, G: ×100; B, E, F, H: ×400).

Fig. 3. Immunohistolocalization of Notch intracellular domain in various fibroproliferative skin diseases and normal skin.

was detected in keratinocytes of the epidermis, hair follicles, sebaceous and eccrine glands, and endothelial cells (Fig. 1E, 2H, 3, Table 1). NICD was highly stained in the upper epidermal layer than in the basal layer (Fig. 1E). Physiological perivascular infiltrating immune cells showed high expression of NICD (Fig. 2H).

DISCUSSION

In the present study, NICD expression levels were determined by immunohistochemical analysis of normal skin, keloid, hypertrophic scar, morphea, and dermatofibroma specimens. Keloids and hypertrophic scars are considered to be fibroblastic or myofibroblastic tumors. Keloid and hypertrophic scar specimens showed moderate to high expression of NICD. Dermatofibroma, a representative...
fibrohistiocytic tumor, also exhibited moderate to high NICD expression in all tumor components. NICD expression was generally low or not detected in normal fibroblasts, and fibroblasts from patients with morphea were strongly stained compared to the normal cells; however, the proportion of NICD-immunopositive cells in normal fibroblasts was much lower than that of keloids, hypertrophic scars, and dermatofibromas. In contrast, significant staining of NICD in fibroblasts was observed only in various fibroproliferative skin diseases, and the accumulation of NICD in keratinocytes and endothelial cells was also observed in fibroproliferative diseases as well as normal controls.

The Notch signaling pathway is involved in the normal wound healing process by modulating keratinocytes, fibroblasts, and endothelial cells\(^9\). Keloids and hypertrophic scars have been considered to be aberrant wound healing consequences\(^1\). The significant upregulation of the NICD in keloid fibroblasts observed in the present study is consistent with previous studies\(^9,10,14\). Keloid fibroblasts express NICD-1 (54.5%), NICD-2 (38.6%), and JAG-1 at mRNA and protein levels\(^14\). The inhibition of Notch signaling via JAG-1 knockdown led to the inhibition of proliferation, migration, and invasion properties of keloid fibroblasts\(^14\). Dees et al.\(^9\) reported that significant staining of NICD in keloid and hypertrophic scar fibroblasts was also observed in specimens from patients with systemic sclerosis. However, our results showed that the immunoreactivity for NICD in keloids and hypertrophic scars was much higher than that in morphea. These results may be attributed to the fact that the proliferative, migratory, and invasive potential of myofibroblasts and fibroblasts in keloids, hypertrophic scars, and dermatofibromas are higher than those in morphea. Although morphea is considered to be a localized form of scleroderma, it may have different immunopathological characteristics from systemic sclerosis.

Interestingly, the perivascular inflammatory infiltrate from two patients with early stage morphea and one patient with hypertrophic scars showed moderate to high immunopositivity for NICD. Recent evidence suggests the role of immune cells in activation of the Notch signaling pathway in skin fibrosis\(^9,10,14\).

Infiltrating T cells prominently expressed the ligand JAG-1 in human systemic sclerosis and fibroblasts stimulated by recruited inflammatory cells that may release NICD, which transforms tumor cells to adopt invasive phenotypes\(^9\). Keloid samples with abundant immune cells significantly expressed Notch-1 in fibroblasts, but samples with few immune cells showed minimal to no expression of Notch-1 in fibroblasts\(^14\). However, overall, all keloid fibroblasts were immunopositive for NICD, although there was little to no adjacent inflammatory infiltrate in our study. Furthermore, Notch-expressing immune infiltrate in normal control skins was observed in normal control skin and of skin of patients with fibroproliferative diseases. Thus, the pro-fibrotic role of immune cells needs to be further investigated.

NICD was constitutively expressed in normal keratinocytes of the epidermis, hair follicles, sebaceous gland endothelial cells, and immune cells. Notch signaling has been suggested to regulate epidermis and hair follicle homeostasis\(^15,16\). All specimens in our study exhibited high expression of NICD, especially in the upper epithelial layer\(^15\), and Notch-1 was reported to regulate early- and late-stage epidermal differentiation\(^16\). In contrast, the normal skin specimens used in the study by Dees et al.\(^9\) did not show NICD expression in keratinocytes, endothelial cells, and immune cells. This discrepancy is thought to result from differences in methodologies. Thus, there are conflicting results regarding the effects of Notch-1 on skin carcinogenesis\(^2,17\).

The epithelial-to-mesenchymal transition (EMT) is a serial process, which consists of a disassembly of epithelial adherence junctions, morphological changes of epithelial cells to myofibroblasts, degradation of basement membranes, and the migration and invasion of myofibroblasts\(^18\). EMT normally occurs during hair follicle development and the wound repair process, but it occurs excessively in the progression of cancer or pathological fibrotic conditions such as multiple sclerosis and keloids\(^6,19\). This process leads to increased myofibroblast accumulation and scarring\(^11\). Recent evidence has shown that the Notch signaling pathway promotes EMT via interactions with the TGF-\(\beta\) signaling pathway in the kidney tubular epithelium\(^20\).

The Notch signaling pathway is known to modulate angiogenesis in normal tissues and tumors\(^15\), and the inhibition of Notch signaling showed anti-angiogenic effects in keloids\(^14\). Morphea is considered to be a result of the inflammatory cascade following vascular injury\(^13\). Hypoxia, reactive oxygen species, and TGF-\(\beta\) are suggested to be pro-fibrotic factors in various fibroproliferative skin diseases such as morphea and keloids\(^5,21,22\). The Notch signaling molecules in dermal fibroblasts are stimulated by hypoxia\(^9,10\), reactive oxygen species, or elevated levels of Ha-Ras and Ki-Ras\(^23\).

In conclusion, the significant immunoreactivity for the NICD was observed in various fibrotic skin diseases, especially in keloids. In contrast, normal skin keratinocytes,
immune cells, and endothelial cells constitutively expressed NICD. Skin fibroblasts only expressed NICD under pathologically fibrotic conditions. These results suggest a pro-fibrotic role of the Notch signaling pathway in human skin fibrosis. Further studies are required to establish the functional role for the NICD at the molecular level in the development and progression skin fibrosis.

ACKNOWLEDGMENT

This study was supported by a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A110763) and Clinical Research Laboratory of the Catholic University of Korea, St. Paul’s Hospital (2011).

REFERENCES

1. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-647.
2. Bolós V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-363.
3. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-233.
4. Kageyama R, Ohtsuka T, Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 2007;134:1243-1251.
5. Kavian N, Servettaz A, Weill B, Batteux F. New insights into the mechanism of notch signalling in fibrosis. Open Rheumatol J 2012;6:96-102.
6. Aoyagi-Ikeda K, Maeno T, Matsui H, Ueno M, Hara K, Aoki Y, et al. Notch induces myofibroblast differentiation of alveolar epithelial cells via transforming growth factor-beta-Smad3 pathway. Am J Respir Cell Mol Biol 2011;45:136-144.
7. Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 2002;8:979-986.
8. Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 2011;163:141-172.
9. Dees C, Zerr P, Tomcik M, Beyer C, Horn A, Akhmetshina A, et al. Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum 2011;63:1396-1404.
10. Dees C, Tomcik M, Zerr P, Akhmetshina A, Horn A, Palumbo K, et al. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis 2011;70:1304-1310.
11. Shih B, Garside E, McGrouther DA, Bayat A. Molecular dissection of abnormal wound healing processes resulting in keloid disease. Wound Repair Regen 2010;18:139-153.
12. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP. Integration of TGF-beta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 2004;23:1155-1165.
13. Beer TW, Lam MH, Heenan PJ. Tumors of fibrous tissue involving the skin. In: Elder DE, Elenitsas R, Johnson BL, Murphy GF, Xu X, editors. Lever’s histopathology of the skin. 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2009:969-980.
14. Syed F, Bayat A. Notch signaling pathway in keloid disease: enhanced fibroblast activity in a Jagged-1 peptide-dependent manner in lesional vs. extralesional fibroblasts. Wound Repair Regen 2012;20:688-706.
15. Okuyama R, Tagami H, Aiba S. Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci 2008;49:187-194.
16. Lin HY, Kao CH, Lin KM, Kaartinen V, Yang LT. Notch signaling regulates late-stage epidermal differentiation and maintains postnatal hair cycle homeostasis. PLoS One 2011;6:e15842.
17. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-542.
18. Matsuno Y, Coelho AL, Jarai G, Westwick J, Hogaboam CM. Notch signaling mediates TGF-beta-1-induced epithelial-mesenchymal transition through the induction of Snai1. Int J Biochem Cell Biol 2012;44:776-789.
19. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
20. Nyhan KC, Faherty N, Murray G, Coeoy LB, Godson C, Crean JK, et al. Jagged/Notch signalling is required for a subset of TGF beta 1 responses in human kidney epithelial cells. Biochim Biophys Acta 2010;1803:1386-1395.
21. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008;105:6392-6397.
22. Ryu DY, Yang Y, Ha H, Lee GT, Song JS, Uh ST, et al. Role of reactive oxygen species in TGF-beta1-induced mitogen-activated protein kinase activation and epithelial-mesenchymal transition in renal tubular epithelial cells. J Am Soc Nephrol 2005;16:667-675.
23. Svegliati S, Cancelllo R, Sambo P, Luchetti M, Paroncini P, Orlandini G, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem 2005;280:36474-36482.